核药（RDC）全称放射性药物，是指含有放射性同位素、用于疾病诊断、治疗或医学研究的特殊药 物。核药正革命性地改变着疾病的诊疗方式，也是各国生物医药产业竞相布局的战略高地。当前，全球 十大制药企业已相继进入该赛道，纷纷布局治疗用放射性核素偶联药物的研发。 成立不久，白云山稀核健康技术团队便在哈尔滨医科大学附属第四医院利用自主研发的先进国产固体靶 系统，成功实现了锆-89的高质量制备，填补了国内空白。 本报讯 （记者王镜茹）今年8月，广州医药集团有限公司（以下简称"广药集团"）同厦门稀土所成果转 化平台，共同出资成立广州白云山（600332）稀核健康医药有限公司（以下简称"白云山稀核健康"）， 正式宣告将全面布局核药新赛道。 目前，广药集团已制定清晰目标：短期基于自主开发的"固体靶"技术，快速产业化稀土诊断、治疗型核 素产品；中期计划建设基于中高能加速器的核素生产研发基地，推动新型α治疗核素研发与规模化生 产，并布局多条RDC研发管线；长期则致力于提供具有广药集团特色的智慧核医疗解决方案。 近年来，为支持核医疗产业发展，国家相继出台《医用同位素中长期发展规划（2021—2035年）》等顶 层设计，明确支持技术研发 ...

Group 1 - The Hunan China Nuclear Tumor Hospital (Phase I) project has officially topped out on June 14, 2023, with an expected completion and opening in 2026 [1] - The project covers a total construction area of approximately 330,000 square meters, with a planned capacity of 1,800 beds (917 beds for Phase I) and a total investment exceeding 3 billion yuan [3] - The hospital is positioned as a nuclear medical center and flagship oncology specialty hospital in Central and Southern China, equipped with advanced medical technologies such as proton heavy ion therapy systems and BNCT systems [3] Group 2 - The project is a result of a strategic cooperation agreement signed in 2017 between China National Nuclear Corporation (CNNC) and the Hunan Provincial Government, aimed at establishing the CNNC Hunan Proton Medical Center [4] - CNNC Health, as a professional platform for nuclear medical industry investment and management, is collaborating with local government to implement the "Healthy China" strategy and ensure the project is included as a key provincial and municipal engineering project [4] - The hospital aims to integrate various resources in the Yuhua District to activate a "nuclear medical innovation ecosystem," focusing on tumor diagnosis and driving the development of nuclear drug research, nuclear medical equipment manufacturing, and talent cultivation [6]